Výsledky vyhledávání - "M. Yu. Zubareva"

Akademický článek

ASSESSMENT OF THE EFFECT OF RS2230806 ALLELIC VARIANT IN THE ABCA1 GENE ON THE LIPID-LOWERING EFFECTS OF ATORVASTATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Autor: G. P. Smirnov, T. A. Rozhkova, M. Yu. Zubareva, Yu. A. Shuvalova, D. V. Rebrikov, A. I. Kaminny, V. N. Titov, V. V. Kukharchuk, P. P. Malyshev

Publikováno v: Атеросклероз, Vol 14, Iss 3, Pp 20-27 (2018)

Objective: to evaluate the effect of rs2230806 variant in the ABCA1 gene on lipid and apolipoprotein (apo)A-I and apoB levels after the atorvastatin treatment in patients with heterozygous familial hypercholesterolemia (FH). Material and methods. The

Externí odkaz: https://doaj.org/article/9d35c6795c5e4ce396088008f7251949

Zobrazit plný text záznamu

Akademický článek

Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines

Autor: A. V. Susekov, M. Yu. Zubareva, T. A. Rozhkova, V. P. Masenko

Publikováno v: Кардиоваскулярная терапия и профилактика, Vol 10, Iss 6, Pp 81-88 (2011)

Aim. To assess the effects of original statins as monotherapy or in combination with ezetimibe on the levels of proinflammatory cytokines and high-sensitive C-reactive protein (hsCRP) in patients with coronary heart disease (CHD) and hyperlipidemia (

Externí odkaz: https://doaj.org/article/1b1d2b863d934be39c043fd16699f8d5

Zobrazit plný text záznamu

Akademický článek

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia

Autor: M. Yu. Zubareva, T. A. Rozhkova, E. Yu. Solovyeva, A. V. Susekov

Publikováno v: Кардиоваскулярная терапия и профилактика, Vol 9, Iss 6, Pp 74-82 (2010)

Aim. To study the lipid-lowering effectiveness, as well as the effects on inflammatory markers and vascular wall function, of ezetimibe as monotherapy and in combination with initial doses of original statins (simvastatin, atorvastatin, and rosuvasta

Externí odkaz: https://doaj.org/article/7486f6539fd04d2eb025942954437df4

Zobrazit plný text záznamu

Akademický článek

Double cholesterol inhibition — a new approach to effective control of hyperlipidemia and atherosclerosis

Autor: A. V. Susekov, N. B. Gornyakova, M. Yu. Zubareva, T. A. Rozhkova, E. Yu. Solovyeva

Publikováno v: Кардиоваскулярная терапия и профилактика, Vol 8, Iss 6, Pp 98-110 (2009)

The increased level of low-density lipoprotein cholesterol (LDL-CH) is one of the risk factors (RFs) of coronary heart disease and atherosclerosis. Statins, with their vast evidence base on mortality reduction, are the principal medications in athero

Externí odkaz: https://doaj.org/article/6836815ef96543199b2c96ad5b35161c

Zobrazit plný text záznamu

Akademický článek

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness

Autor: A. V. Susekov, T. A. Rozhkova, M. I. Tripoten’, O. A. Pogorelova, B. D. Kulev, T. V. Balakhonova, M. Yu. Zubareva, V. P. Masenko, A. N. Rogoza, V. V. Kukharchuk

Publikováno v: Кардиоваскулярная терапия и профилактика, Vol 6, Iss 3, Pp 68-75 (2007)

Aim. To study atorvastatin (10 and 20 mg/d) effects on lipid, C-reactive protein, and fibrinogen levels, vascular wall structure and function in patients with coronary heart disease (CHD) and primary hyperlipidemia (PHL). Material and methods. In tot

Externí odkaz: https://doaj.org/article/51b53046474d4fb3bf803e09e0b94ae5

Zobrazit plný text záznamu

Akademický článek

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels

Autor: A. V. Susekov, M. Yu. Zubareva, M. I. Tripoten’, T. A. Rozhkova, O. A. Pogorelova, T. V. Balakhonova, V. P. Masenko, V. V. Kukharchuk

Publikováno v: Кардиоваскулярная терапия и профилактика, Vol 5, Iss 6, Pp 37-45 (2006)

Aim. To compare effects of atorvastatin in the doses of 10 and 20 mg/d on lipid profile, C-reactive protein (hsCRP), fibrinogen levels, as well as vascular wall structure and function in patients with coronary heart disease (CHD) and primary hyperlip

Externí odkaz: https://doaj.org/article/8a2edd32edf14d95b678413b53afd0f9

Zobrazit plný text záznamu

Akademický článek

ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk

Autor: I V Sergienko, A A Ansheles, O M Drapkina, N B Gornyakova, M Yu Zubareva, R N Shepel, V V Kuharchuk, S A Boytsov

Publikováno v: Терапевтический архив, Vol 91, Iss 4, Pp 90-98 (2019)

Reducing the risk of cardiovascular complications include lifestyle changes, drug therapy for achieving target blood pressure levels, normalizing the lipid profile, and correcting other risk factors. Adherence to therapy is of particular role, especi

Externí odkaz: https://doaj.org/article/6bdca43d27954cb695387d95ccf2f6ea

Zobrazit plný text záznamu

Akademický článek

Evidence-based grounds of the efficacy of simvastatin (zocor): 15 years later

Autor: Andrey Vladimirovich Susekov, Natal'ya Badrievna Gornyakova, Marina Yur'evna Zubareva, A V Susekov, N B Gornyakova, M Yu Zubareva

Publikováno v: Терапевтический архив, Vol 82, Iss 12, Pp 68-72 (2010)

The review describes the history of hypolipidemic therapy with statins. It gives the results of studies of the primary prevention of atherosclerosis and the treatment of hyperlipidemias with lovastatin, pravastatin, and fluvastatin. Emphasis is laid

Externí odkaz: https://doaj.org/article/73cbd3091e4b44f998af48608fc6ab19

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání